Overall verdict
Neutral
6.4/10
1-year performance
+23.28%
Score breakdown
Up 23.3% over 1 year, 86% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 3.2/10.
27 analysts, target +0.0% vs the price.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases.
Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments ;
immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases ; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products ;
transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market ; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Marc Casper
Founded
1956
Employees
125 000
Revenue / employee
356 448 USD
Next earnings
October 21, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.8.36%
- VANGUARD CAPITAL MANAGEMENT LLC6.57%
- STATE STREET CORP4.55%
- FMR LLC3.81%
- MORGAN STANLEY2.91%
- JPMORGAN CHASE & CO2.30%
- GEODE CAPITAL MANAGEMENT, LLC2.27%
- FRANKLIN RESOURCES INC1.97%
- VANGUARD PORTFOLIO MANAGEMENT LLC1.68%
- Other institutions55.98%
- Rest of the register9.61%
2615 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
694.33 USD
52-week low
435.27 USD
1-year performance
23.28%
Rising
Year-to-date performance
13.55%
Rising
Drawdown
-5.23%
Mild pullback
Position in the 52-week range
86% of range
Against the world ETF
Over 17 years, from September 2009 to September 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of September 2009 are worth today
| Thermo Fisher | $163,678 |
| World ETF | $60,004 |
| S&P 500 | $97,541 |
| Risk-free placement | $12,831 |
The risk
- Shaking:the share moves 1.8 times as much as the world ETF.
- Worst fall:-41 % between December 2021 and June 2025. $10,000 placed at the top fell to $5,905. The world ETF, at worst: -34 %. Back to its high in 15 months.
Thermo Fisher earned 3 times as much as the world ETF since 2009
Value of $10,000 placed at the end of September 2009, dividends reinvested, in dollars
- Thermo Fisher: $163,678
- World ETF: $60,004
- S&P 500: $97,541
- Risk-free placement: $12,831
Based on past performance. This is not a recommendation.
Range: 436.68 USD - 577.50 USD (comparables only)
The price implies growth of 11.64% per year; the company grows at 2.11%.
Gross margin 40.2%, net margin 15.0%, ROIC 7.9%, ROE 13.5%.
Net margin
15.04%
Exceptional
Sector 5.42%|S&P 13.13%
Gross margin
40.19%
Fair
Return on equity (ROE)
13.51%
Exceptional
Sector 2.79%|S&P 16.52%
Return on invested capital (ROIC)
7.95%
Exceptional
Free cash flow margin (FCF)
15.79%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.05x
High
Margin stability
3.0 pts
Steady
Revenue to net income
Growth
3.2/10Revenue up 10.5% over 1 year, 6.7% a year over 5, EPS 2.1% a year over 5.
Revenue (trailing 12 months)
46.3Md USD
Revenue growth (1y)
10.49%
Strong
Revenue growth (3y)
-0.80%
Declining
EPS growth (1y)
9.38%
Moderate
EPS CAGR (5y)
2.11%
Low
EPS revisions (3 months)
1.12%
Revised up
Valuation
4.3/10P/E 35.4x, forward P/E 32.7x, EV/EBITDA 23.9x, PEG 16.78. The multiple sits in the 89th percentile of its own 5-year history.
P/E (TTM)
35.4x
Fair
Sector 51.8x|S&P 23.5x
Forward P/E
32.7x
Fair
EV / EBITDA
23.9x
Fair
Sector 27.7x|S&P 14.7x
PEG
16.78
Very expensive
Sector 1.76|S&P 0.87
Fair value (reverse DCF)
507.09 USD
Overvalued
P/E vs its own 5-year history
among the 11% highest valuations
At its historical high
Market cap
243Md USD
Financial strength
5.2/10Cash covers 9.6% of the debt, net debt/EBITDA 2.8x.
Net debt / EBITDA
2.8x
Stretched
Gearing (net debt / equity)
72.86%
Tight
Cash
4.1Md USD
Cash / market cap
1.67%
Stretched
Cash / total debt
9.58%
Stretched
Interest coverage
5.6x
Solid
Net debt
38.5Md USD
Equity
52.8Md USD
Closed daily candles, 2 years
Last close on October 9, 2026: 658.02 USD
- MM20659.76
- MM50626.41
- MM200544.94
- RSI 1454.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.57%
200-day average slope, 3 months
+3.25%
50-day average slope, 1 month
+8.65%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.80 % per day
Volatility change
-10.26%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 20.13 (9) | 25.13 (26) | 47 877 (25) | 12 497 (17) | 7 466 (6) |
| 2027 | 22.91 (10) | 27.58 (27) | 50 341 (25) | 13 450 (17) | 8 249 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 9, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.3 | 8.0 | 71.5Md USD | 21.6x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.8 % | 40.9 % | ||
| 2 | IQV | 7.5 | 7.0 | 42.8Md USD | 32.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.1 % | 28.0 % | ||
| 3 | A207940 | 7.4 | 8.0 | 43.4Md USD | 28.6x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.4 % | -21.3 % | ||
| 4 | A | 6.8 | 7.0 | 48.1Md USD | 33.6x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.6 % | 21.6 % | ||
| 5 | DHR | 6.5 | 6.5 | 155Md USD | 39.0x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 7.3 % | ||
| 6 | TMO | 6.4 | 5.6 | 243Md USD | 35.4x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 23.3 % | ||
| 7 | LONN | 6.3 | 6.1 | 46.9Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 5.5 % | ||
| 8 | ILMN | 5.2 | 5.1 | 42.0Md USD | 51.8x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.2 % | 184.9 % | ||
| 9 | WAT | 5.2 | 3.7 | 42.6Md USD | 108.3x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 32.5 % |
